The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLL.L Regulatory News (CLL)

  • There is currently no data for CLL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Pre-close trading update

22 Jul 2010 07:00

RNS Number : 7231P
Cello Group plc
22 July 2010
 



22 July 2010

 

Cello Group plc

 

Pre-close trading update

 

Cello Group (AIM: CLL, 'Cello', or 'the Group'), the leading independent market research and consulting group, publishes a trading update for the six months to 30 June 2010. Cello has continued to trade well and will show like for like income growth and double digit operating profit growth for the first half of the financial year.

 

The Group continues to experience growing income from its international blue chip client base, with particular growth arising from the US, where further organic investment is planned for the second half of the year. Income from UK clients has held up well, with several notable private sector wins, while as anticipated there are likely to be further declines in public sector income over the coming months.

 

The like for like income growth achieved, combined with a lower cost base as a result of pro-active action taken in 2009, are expected to lead to a healthy improvement in profitability in 2010.

 

Divisional trading

 

The Research and Consulting division continues to trade strongly, returning to like for like income growth. This has been driven by continued robustness in core client activity levels, most notably in pharmaceutical and health related sectors, as well as the growing international revenues.

 

The recent investments made to increase the Group's overseas capabilities have begun to bear fruit. Cello recently relocated its US business into a new office in New York. This will act as a resource hub for other Group brands as they continue to build their US client base.

 

New business activity has increased markedly, with notable major project wins from ITV, GSK, Visa Europe, 3M, AG Barr, BA, Expedia, Heineken, Mars Petfood, Unilever, Electronic Arts, Sony, Nokia, Adidas, Miele, Eurostar, MerckSerono, HP, Canon, Epson, Brother, P&G Airwave and Green-works. As a result, the division has a strong pipeline of committed work into the second half of the year, which will more than offset the expected decline in public sector work.

 

Tangible, Cello's response communications business, as expected, saw slight like for like decline in operating income in the first half. The income decline largely occurred due to certain public sector clients not repeating their programmes in 2010.

 

The business now operates out of three office hubs in Edinburgh, London and Cheltenham which is yielding both clear cost benefits, as well as professional and client benefits. A major cost reduction exercise was also undertaken last year, which with these structural changes, mean that operating margins in the current financial year have been substantially protected.

 

There has been a good series of major client wins by Tangible including Scottish and Southern Energy, Sainsbury's Bank, Reckitt Benckiser, O2, Chartis, SPX, SQA. Macmillan Cancer Care, The Sun (Scottish), Avon, Pfizer, Ben & Jerrys, Nandos and Matalan. The benefit of many of these wins will be seen in the second half of the year.

 

Given Tangible's strong flow of private sector client wins, and a more efficient cost base, the Group is confident that Tangible will be substantially ahead of 2009 on a full year basis.

Full year outlook

 

Revenue visibility for the next quarter remains solid and, subject to proper conversion of existing client opportunities, the Board is optimistic for a good full year outcome.

 

Mark Scott, Cello Chief Executive, commented:

 

 "We are pleased with our trading performance and like for like income growth levels in the first half of the year. We are seeing the benefits from our international investment programme initiated two years ago.

 

"The continued growth of income from our long term multi-national blue chip client base, both in the UK and internationally, has more than offset the expected weaker performance from our UK public sector clients. We are set well for the remainder of the year.

 

"Separately I am also delighted to welcome Paul Walton to the Board. As a senior client advisor and strategist, he will undoubtedly continue to make a substantial contribution across the Group"

 

The Group expects to publish its interim results on Tuesday 14 September 2010.

 

Enquiries:

 

Cello Group

020 7812 8460

Mark Scott, Chief Executive

Mark Bentley, Finance Director

Altium

020 7484 4040

Ben Thorne

Paul Chamberlain

College Hill

020 7457 2020

Adrian Duffield/Rozi Morris

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTEAKXFAFFEEFF
Date   Source Headline
11th Aug 20201:38 pmRNSForm 8.3 - Cello Health Plc
11th Aug 202012:05 pmRNSForm 8.3 - Cello Health Plc
11th Aug 202011:34 amRNSForm 8.3 - [Cello Health plc]
11th Aug 202010:07 amRNSScheme of Arrangement becomes Effective
11th Aug 20208:49 amPRNForm 8.3 - Cello Health Plc
11th Aug 20207:30 amRNSSuspension - Cello Health Plc
10th Aug 20202:30 pmRNSForm 8 (DD) - Cello Health plc
10th Aug 20202:30 pmRNSForm 8 (DD) - Cello Health plc
10th Aug 20202:30 pmRNSForm 8 (DD) - Cello Health plc
10th Aug 20202:30 pmRNSForm 8 (DD) - Cello Health plc
10th Aug 202012:12 pmRNSRelevant Securities in Issue
10th Aug 202011:02 amRNSForm 8.3 - Cello Health PLC
10th Aug 20208:54 amRNSExercise of Options
10th Aug 20208:06 amRNSForm 8.5 (EPT/NON-RI)
7th Aug 20203:16 pmRNSForm 8.3 - CELLO HEALTH PLC
7th Aug 20203:04 pmRNSCourt Sanction of Scheme
7th Aug 202012:52 pmRNSAdditional Block Listing of Ordinary Shares
6th Aug 202011:01 amRNSForm 8.3 - Cello Health PLC
5th Aug 20201:34 pmRNSForm 8.3 - Cello Health Plc
4th Aug 20205:30 pmRNSCello Health
4th Aug 202012:39 pmRNSForm 8.3 - Cello Health PLC
4th Aug 20208:21 amRNSForm 8.5 (EPT/NON-RI)
3rd Aug 202012:57 pmRNSResults of Court Meeting and General Meeting
3rd Aug 202010:53 amRNSForm 8.3 - CELLO GROUP PLC
31st Jul 202012:39 pmRNSForm 8.3 - CELLO GROUP PLC
31st Jul 202011:46 amRNSForm 8.3 - Cello Health PLC
31st Jul 20208:34 amRNSForm 8.5 (EPT/NON-RI)
31st Jul 20207:58 amRNSForm 8.3 - Cello Health PLC
30th Jul 20205:11 pmRNSHolding(s) in Company
30th Jul 20208:03 amRNSForm 8.3 - Cello Health Plc
29th Jul 202012:49 pmRNSHolding(s) in Company
29th Jul 20208:30 amRNSForm 8.5 (EPT/NON-RI)
28th Jul 20206:18 pmRNSUpdate on letters of intent
28th Jul 20203:17 pmRNSForm 8.3 - CELLO HEALTH PLC
28th Jul 20202:46 pmRNSForm 8.3 - Cello Health PLC
28th Jul 20202:04 pmRNSNotification of Major Holdings
28th Jul 20201:24 pmRNSCELLO HEALTH PLC ORD GBP0.10
28th Jul 202011:36 amGNWForm 8.3 - [Cello Health plc] - (HHL)
28th Jul 202011:17 amRNSForm 8.3 - Cello Health Plc
28th Jul 20208:45 amRNSForm 8.5 (EPT/NON-RI)
27th Jul 20203:17 pmRNSForm 8.3 - [CELLO HEALTH PLC
27th Jul 20207:00 amRNSHolding(s) in Company
23rd Jul 20203:29 pmRNSForm 8.3 - Cello Health PLC
22nd Jul 202012:33 pmRNSForm 8.3 - Cello Health PLC
22nd Jul 202011:38 amRNSFORM 8.3 - Cello Health Plc
21st Jul 20203:15 pmBUSForm 8.3 - Cello Health plc
21st Jul 20202:35 pmRNSForm 8.3 - Cello Health PLC
21st Jul 202012:18 pmRNSBlock Listing Update & Total Voting Rights
21st Jul 20207:00 amRNSHolding(s) in Company
20th Jul 20203:15 pmBUSForm 8.3 - Cello Health plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.